Dr. Reddy's Laboratories Limited (RDY)
- Previous Close
79.48 - Open
79.67 - Bid 79.55 x 900
- Ask --
- Day's Range
79.39 - 80.13 - 52 Week Range
63.72 - 84.46 - Volume
99,549 - Avg. Volume
209,141 - Market Cap (intraday)
13.344B - Beta (5Y Monthly) 0.34
- PE Ratio (TTM)
19.93 - EPS (TTM)
3.99 - Earnings Date Oct 25, 2024 - Oct 29, 2024
- Forward Dividend & Yield 0.48 (0.60%)
- Ex-Dividend Date Jul 30, 2024
- 1y Target Est
85.80
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
www.drreddys.com27,048
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: RDY
View MoreResearch Reports: RDY
View MorePerformance Overview: RDY
Trailing total returns as of 9/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RDY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RDY
View MoreValuation Measures
Market Cap
13.34B
Enterprise Value
12.58B
Trailing P/E
19.94
Forward P/E
21.37
PEG Ratio (5yr expected)
4.57
Price/Sales (ttm)
3.84
Price/Book (mrq)
3.76
Enterprise Value/Revenue
3.64
Enterprise Value/EBITDA
11.82
Financial Highlights
Profitability and Income Statement
Profit Margin
19.26%
Return on Assets (ttm)
10.93%
Return on Equity (ttm)
20.59%
Revenue (ttm)
288.51B
Net Income Avi to Common (ttm)
55.58B
Diluted EPS (ttm)
3.99
Balance Sheet and Cash Flow
Total Cash (mrq)
94.63B
Total Debt/Equity (mrq)
10.41%
Levered Free Cash Flow (ttm)
17.53B